EDIT
Editas Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.42
+2.98%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.38
From 52W high−41.55%
Volume2.01M
Market cap$371.66M
P/E (TTM)—
P/S (TTM)7.9x
Div yield—
Key dataOct 19, 2026
Open
$2.38
From 52W high
−41.55%
Volume
2.01M
Market cap
$371.66M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
38.8
MomentumView details →
1D Return
+2.98%
YTD Return
+13.41%
SummaryUpdated Jun 1, 2026
Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotechnology company founded in 2013 and based in Cambridge, Massachusetts. The company was originally incorporated as Gengine, Inc. before changing its name in November 2013. Editas went public in February 2016 and has since established itself as a pioneer in the genome editing field, focusing on developing transformative genomic medicines using CRISPR technology to treat serious diseases. The company operates primarily in the gene therapy and cell therapy sectors, with programs targeting inherited diseases, blood disorders, and cancer.
Similar companies
Latest newsMore news →
Editas Medicine, Inc. received approval to initiate its Phase 1/2 Strive clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia.11d agoEditas Medicine granted an inducement award to its newly appointed Chief Medical Officer, Daniel Ory, M.D., on September 9, 2026.40d ago